
Jack Hirsh, Gordon Guyatt, Gregory W. Albers, Robert Harrington and Holger J. Schünemann

Chest 2008;133;110-112
DOI 10.1378/chest.08-0652

The online version of this article, along with updated information and services can be found online on the World Wide Web at: http://chestjournal.org/cgi/content/abstract/133/6_suppl/110S
Antithrombotic and Thrombolytic Therapy*

American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)

Jack Hirsh, MD, FCCP, Chair; Gordon Guyatt, MD, FCCP; Gregory W. Albers, MD; Robert Harrington, MD, FCCP; and Holger J. Schülemann, MD, PhD, FCCP

Since publication of the seventh American College of Chest Physicians (ACCP) supplement on antithrombotic and thrombolytic therapy, the results of clinical trials have provided important new information on the management of thromboembolic disorders, and the science of developing recommendations has advanced. In the accompanying supplement, we provide the new and updated recommendations and review several important changes that we have made in our guideline development process.

We again made a conscious effort to increase the participation of female authors and contributors from outside North America, the latter reflecting the widespread use and dissemination of these guidelines internationally. The grading system for the recommendations was adopted in 2006 by the ACCP for all its guidelines, is similar to the increasingly widely used Grades of Recommendation, Assessment, Development, and Evaluation approach, and is described in detail in one of the introductory chapters.

While most of the evidence on which recommendations are made remains low quality in fields of pediatric thrombosis, thrombosis in pregnancy, and thrombosis in valvular heart disease, rigorous studies in other fields have resulted in new and strong evidence-based recommendations for many indications.

(CHEST 2008; 133:110S–112S)

Abbreviation: ACCP = American College of Chest Physicians
comprehensive literature searches for evidence relevant to these specific questions or recommendations. Authors reviewed citations and applied the predefined criteria to ascertain whether studies contributed to the evidence that underlies the recommendations.

Once again to ensure transparency and explicitness among questions, evidence, and recommendations, we use a numbering scheme to ensure that the number associated with the explicitly defined questions presented in the summary table of each chapter corresponds to the number of the section laying out the evidence, as well as any corresponding recommendations. This scheme allows readers to quickly identify the underlying question associated with each recommendation, and the relevant evidence.

The grading system in the eighth edition of the ACCP guidelines now reflects the system adopted for all ACCP guidelines, and is similar to the Grades of Recommendation, Assessment, Development, and Evaluation system, which is being widely adopted by many guideline groups. As in the 2004 guidelines, if experts are very certain that benefits do or do not outweigh risks, burden, and costs, they will make a strong recommendation, in our formulation, Grade 1. If they are less certain of the magnitude of the benefits and risks, burden, and costs, and thus their relative impact, they make a weaker, Grade 2, recommendation.

The system also provides a rating of the quality of evidence (high quality, moderate quality, and low quality: “A,” “B,” and “C,” respectively). The important changes in quality rating from 2004 are more explicitness in the criteria for downgrading or upgrading evidence, and designating high-quality evidence from observational studies with large effects as “A” rather than “C.” Randomized trials provide high-quality evidence unless they suffer from limitations in design and execution, imprecision, indirectness, inconsistency, or reporting bias. Observational studies provide weak evidence unless there are no obvious biases and the effects are very large and consistent.

While conference participants agreed that recommendations should reflect economic considerations, incorporating costs is fraught with difficult challenges. For most recommendations, formal economic analyses are unavailable. Even when analyses are available, they may be methodologically weak or biased. Furthermore, costs differ radically across jurisdictions, and even sometimes across hospitals within jurisdictions. Thus, we have omitted resource allocation considerations from all but a few recommendations in which these issues are particularly important, and in which informative evidence from economic analyses are available. For these recommendations, we obtained guidance from health economists whose observations are included in the relevant discussions.

As in the 2004 recommendations, we endeavored to stay alert to the patient and community values and preferences underlying our recommendations. Once again, when values and preferences were particularly salient, we identified the underlying values associated with particular recommendations. For the first time, three individuals with a special interest, knowledge, and perspective in how values and preferences influence recommendations provided input into the guidelines.

Although the rigor with which trials for many indications are evaluated has improved dramatically, the evidence remains weak in fields of pediatric thrombosis, thrombosis in pregnancy, and thrombosis in valvular heart disease. This deficiency needs to be addressed.

**Conflict of Interest Disclosures**

**Dr. Hirsch** discloses that he has received partial support for writing two books, one on Fondaparinux and one on low-molecular-weight heparin.

**Dr. Albers** discloses that he has received grant monies from the National Institutes of Health, Astra, Genentech, Bristol-Myers Squibb, Sanofi, Boehringer Ingelheim, NMT Medical, and Aventis. He is also on the speakers bureau for Boehringer Ingelheim, and advisory committees for Astra, Aventis, Boehringer Ingelheim, NMT Medical, Bristol-Myers Squibb, and Sanofi.

**Dr. Guyatt** reveals no real or potential conflicts of interest or commitment.

**Dr. Harrington** discloses that he holds a fiduciary position as Director of the Duke Clinical Research Institute (DCRI). Either he or the DCRI have received grant monies from the following: Abbott Laboratories; Abbott Vascular Business; Acorn Cardiovascular; Actelion, Ltd; Acusphere, Inc; Adolor Corporation; Advanced Cardiovascular Systems, Inc; Air Products: PLC; Ajinomoto; Alexion, Inc; Allergan, Inc; Alkion Corporation; Amgen, Inc; Amnyn Pharmaceuticals; Anadys; Ang Kmedical Systems, Inc; AnGe MG Inc; Angiometrix, Inc; Arginex Pharmaceuticals; Ark Therapeutics; Astellas Pharma US; Astra Hasl; AstraZeneca; Attitech; Aventis; BARRX Medical, Inc; Baxter; Bayer AG; Bayer Corporation US; Berlex, Inc; Bioheart; Biodex Therapeutics; Biosense Webster, Inc; Biosite, Inc (also Biosite Diagnostics); Biosynex; Boehringer Ingelheim; Boston MedTech Advisors; Bristol Scientific Corporation; Bristol-Myers Squibb; CanAm Bioscience; Cardio Thoracic Systems; CardioDynamics International; CardioKinetix; CardioOptics; Celgene Corporation; Celsion Corporation; Centocor; Cerexa, Inc; Chase Medical; Chugai Pharmaceutical; Cierra Inc; Coley Pharmaceutical Group; Conover Medsystems; Corus Coris Genetics; Cordis; Critical Therapeutics; Cubist Pharmaceuticals; CV Therapeutics; Cytokinetics; Daiichi Sankyo deCode Genetics; Dyax; EchoSens, Inc; Eclipse Surgical Technologies; Edwards Lifesciences; Eli Lilly & Company; EnteroMedics; Enzon Pharmaceutical; EOS Electric Optical Systems; EPI-Q, Inc; ev3, Inc; Evalve, Inc; Flow Cardia Inc; Fox Hollow Pharmaceuticals; Fujisawa; Genentech; General Electric Company; General Electric Healthcare; General Electric Medical Systems; Genzyme Corporation; Getz Bros & Co.
Inc; GlaxoSmithKline; Globelimmune; Gloucester Pharmaceuticals; Guidant Pharmaceuticals; Heartscape Technologies; Hoffmann-LaRoche; Human Genome Sciences, Inc; ICAGEN; iCo Therapeutics; IDB Medical; Idenix Pharmaceuticals; Indigo Pharmaceutical; INFORMD, Inc; InfraReDx; Inhibitex; Innocoll Pharmaceuticals; Inspire Pharmaceuticals; Intarcia Therapeutics; Integrated Therapeutics Group; Inverness Medical Innovations; Ischemix, Inc; Johnson & Johnson; Jomed, Inc; KAI Pharmaceuticals; Kerberos Proximal Solutions, Inc; Kinetic Concepts, Inc; King Pharmaceuticals; Kuhera Chemical Co; Lilly; Lumen Biomedical, Inc; Medical Education Solutions Group; Medicure International; MiniMed; Medi-Flex, Inc; MedImmune; Medtronic Ave; Medtronic Diabetes; Medtronic, Inc; Medtronic Vascular; Merck Group; Microphage, Inc; Millennium Pharmaceutical; Mosby; Mycosol, Inc; NABI Biopharma; Neuron Pharmaceuticals; NicOx; NitroMed; Novartis AG Group; Novartis Pharmaceuticals; OLG Research; Ortho Biotech; OSI Eyetech; Osiris Therapeutics; Otaka Pharmaceutical; Pathway Medical Technologies; PDL bio Pharma; PDXRs, Inc; Peregrine Pharmaceuticals; Pfizer; Pharmacies; Pharmasset; Pharsight, Inc; Portola Pharmaceutical; Proctor & Gamble; Radiant; Reata Pharmaceuticals; Recom Managed Systems, Inc; Regado Biosciences; Reliant Pharmaceuticals; Roche Diagnostic Corp; Salix Pharmaceuticals; Sanofi Pasteur, Inc (formerly Aventis-Pasteur); Sanofi-Aventis; Sanofi-Synthelabo; Schering-Plough Corporation; Sciclone Pharmaceuticals; Scios; Seredigm; Sichel Technologies; Siemens; Skyline Ventures; Social Scientific Solutions; Spectranetics; Summit; Suneis; TAP Pharmaceutical Products; Tengion; Terumo Corporation; The Medicines Company; Theravance; TherOx, Inc; Thoratec Corporation; Titan Pharmaceuticals; United Therapeutics; Uptake Medical Corporation; Valleylab; Valeant Pharmaceuticals International; Valenti, Inc; Vascular Solutions, Inc; Velocimen, Inc; Veridep; Vertex Pharmaceuticals; VIAYS Healthcare; Vicuron Pharmaceuticals (formerly Versico): ViroChem Pharma, Inc; Watson Pharmaceuticals; WebMD; Wyeth; Xsira Pharmaceuticals (formerly Norak Biosciences); and/or XTL Biopharma.

Dr. Schünemann discloses that in addition to receiving grant monies from Physicians Services Inc Foundation, he has also received unrestricted grants from Leo Pharmaceutical and Bayer. He has served on the speakers bureau of AstraZeneca, Bayer, Boehringer Ingelheim, and Sanofi-Aventis, and has assisted the advisory committees of Boehringer Ingelheim, and AstraZeneca.

REFERENCES

Jack Hirsh, Gordon Guyatt, Gregory W. Albers, Robert Harrington and Holger J. Schünemann
_CHEST_ 2008;133;110-112
DOI 10.1378/chest.08-0652

This information is current as of June 24, 2008

<table>
<thead>
<tr>
<th>Updated Information &amp; Services</th>
<th>Updated information and services, including high-resolution figures, can be found at: <a href="http://chestjournal.org/cgi/content/full/133/6_suppl/110S">http://chestjournal.org/cgi/content/full/133/6_suppl/110S</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Supplementary Material</td>
<td>Supplementary material can be found at: <a href="http://chestjournal.org/cgi/content/full/133/6_suppl/110S/DC1">http://chestjournal.org/cgi/content/full/133/6_suppl/110S/DC1</a></td>
</tr>
<tr>
<td>Permissions &amp; Licensing</td>
<td>Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: <a href="http://chestjournal.org/misc/reprints.shtml">http://chestjournal.org/misc/reprints.shtml</a></td>
</tr>
<tr>
<td>Reprints</td>
<td>Information about ordering reprints can be found online: <a href="http://chestjournal.org/misc/reprints.shtml">http://chestjournal.org/misc/reprints.shtml</a></td>
</tr>
<tr>
<td>Email alerting service</td>
<td>Receive free email alerts when new articles cite this article sign up in the box at the top right corner of the online article.</td>
</tr>
<tr>
<td>Images in PowerPoint format</td>
<td>Figures that appear in CHEST articles can be downloaded for teaching purposes in PowerPoint slide format. See any online article figure for directions.</td>
</tr>
</tbody>
</table>